X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NW3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels and is devoid of biological activity at >130 other CNS targets. It is under phase 2 clinical development for the treatment of Treatment-resistant Schizophrenia.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
NW3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It is under phase 2 clinical development for the treatment of Schizophrenia.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2023
Details:
NW-3509 (evenamide) is an orally available new chemical entity, specifically blocks voltage-gated sodium channels. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Product Name: Xadago
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zambon Group SpA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
Details:
NW-3509 (evenamide), an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs). It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
NW-3509 (Evenamide), an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs). It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
The data presented confirm NW-3509 (evenamide) potential to improve symptoms of psychosis in patients who, despite treatment with various antipsychotics, continue to experience severe symptoms of psychosis and functional disabilities.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Product Name: Xadago
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Zambon Switzerland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 12, 2021
Details:
Explanatory study 008 is designed to evaluate the safety, tolerability, EEG effects, and preliminary efficacy of two fixed doses of evenamide (7.5 mg and 15 mg BID) in patients with chronic schizophrenia under treatment with a leading second-generation atypical antipsychotics.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021.
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
